bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
Cash from Investing Activities
bluebird bio Inc
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
Cash from Investing Activities
$254.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is bluebird bio Inc's Cash from Investing Activities?
Cash from Investing Activities
254.4m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Cash from Investing Activities amounts to 254.4m USD.
What is bluebird bio Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
22%
Over the last year, the Cash from Investing Activities growth was 22%.